GSA Capital Partners LLP Takes $1.33 Million Position in DexCom, Inc. $DXCM

GSA Capital Partners LLP acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 19,820 shares of the medical device company’s stock, valued at approximately $1,335,000.

Other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a new position in DexCom during the fourth quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom in the 1st quarter valued at $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter valued at $32,000. Wellington Grp LLC grew its stake in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the period. Finally, DV Equities LLC acquired a new stake in shares of DexCom during the 4th quarter worth $36,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 99,794 shares of company stock worth $7,373,321. Company insiders own 0.28% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $88.76 on Tuesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $91.96. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a market capitalization of $33.49 billion, a P/E ratio of 35.08, a P/E/G ratio of 1.51 and a beta of 1.41. The company’s fifty day moving average price is $76.32 and its two-hundred day moving average price is $70.44.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the firm earned $0.48 earnings per share. The company’s revenue was up 13.1% on a year-over-year basis. On average, research analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on DXCM. Truist Financial set a $93.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price target on DexCom in a research report on Friday, July 31st. Benchmark upped their price target on DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Barclays restated an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, UBS Group set a $96.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.